---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-119064"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:15:47.393439+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma Q3 net loss $8.5M; cash $5.4M; Phase 2 starts for COVID and flu drugs in 2025

## Summary
- Net loss of $8.5M ($8.81 per share) vs $4.7M loss in Q3 2023; R&D expense $5.1M, G&A $3.5M.
- Cash and short-term investments $5.4M as of Sept 30, down from $20.8M at Dec 31, 2023.
- Ratutrelvir (COVID) Phase 1 data supports once-daily dosing without ritonavir; Phase 2 targeted in 2025.
- Tivoxavir marboxil (flu) Phase 1 data supports single-dose treatment; Phase 2 targeted in 2025.
- Luba Greenwood appointed to board of directors; shares outstanding 3,025,554 after 25:1 reverse split.

## SEC filing metadata
- accession: 0001104659-24-119064
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465924119064/0001104659-24-119064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465924119064/tm2428509d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-119064
- JSON: https://secwatch.observer/filing/0001104659-24-119064.json
- Plain text: https://secwatch.observer/filing/0001104659-24-119064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.